Scientists track immune cells to improve lung cancer care
NCT ID NCT04432142
Summary
This study aims to understand how the immune system changes in stage III non-small cell lung cancer patients receiving standard treatment. Researchers will observe 45 patients undergoing chemoradiation followed by immunotherapy (durvalumab) to identify immune markers that might predict treatment success. The goal is to gather knowledge that could help doctors personalize future treatments, not to test a new therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Maastricht Radiation Oncology (MAASTRO clinic)
Maastricht, 6229 ET, Netherlands
Conditions
Explore the condition pages connected to this study.